^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients.

Published date:
05/16/2018
Excerpt:
LB was performed at diagnosis (n = 10), at each radiologic evaluation (n = 75) and at the time of progressive disease (PD) (n = 34) in 35 FISH/RNAseq confirmed ALK+ NSCLC patients, treated with ALK-TKI....ALK resistance mutations were detected in samples collected at PD under crizotinib (L1196M+C1156Y), ceritinib (F1174L), brigatinib (F1174V, F1174L+G1202R, D1203N, R1192P) and lorlatinib (F1174L+G1202R).
DOI:
10.1200/JCO.2018.36.15_suppl.e21031
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer

Excerpt:
G1202R, F1174C/L/V, and G1123S mutations have been found to be ceritinib‐resistant in an analysis of patients treated with ceritinib after crizotinib
DOI:
10.1111/cas.13504